Alkermes (ALKS) Share-based Compensation (2010 - 2026)
Alkermes (ALKS) posted quarterly Share-based Compensation of $31.1 million for Q2 2026, up 24.73% year-over-year from $25.0 million in Q2 2025, and up 98.16% quarter-over-quarter from $15.7 million in Q1 2026.
Alkermes (ALKS) Share-based Compensation (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Share-based Compensation for 17 consecutive years, with $31.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 24.73% year-over-year to $31.1 million; the TTM figure through Jun 2026 stood at $73.8 million (down 8.68% YoY), while the FY2025 annual figure was $98.7 million, up 2.15% from the prior year.
- Share-based Compensation rose to $31.1 million in Q2 2026 per ALKS's latest filing, from $15.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $31.1 million in Q2 2026 and bottomed at $622000.0 in Q3 2025.
- Historically, Share-based Compensation has averaged $15.4 million across 5 years, with a median of $16.0 million in 2022.
- On a YoY basis, Share-based Compensation climbed as much as 857.65% in 2025 and fell as far as 88.73% in 2025.
- Alkermes' Share-based Compensation stood at $3.3 million in 2022, then soared by 683.12% to $25.8 million in 2023, then fell by 19.72% to $20.7 million in 2024, then increased by 26.64% to $26.3 million in 2025, then rose by 18.51% to $31.1 million in 2026.
- Business Quant data shows ALKS's Share-based Compensation at $31.1 million in Q2 2026, $15.7 million in Q1 2026, and $26.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.14 Mn |
| Jun 30, 2026 | 31.14 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Sep 30, 2025 | 622,000.00 |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 24.97 Mn |
| Jun 30, 2025 | 24.97 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 20.75 Mn |
| Dec 31, 2024 | 20.75 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Mar 31, 2024 | 11.23 Mn |